Stock Market Today: Another Vaccine-Trial Stumble Clips Wall Street's Optimism

Johnson & Johnson (JNJ) paused a vaccine study, and Eli Lilly (LLY) was forced to do the same on a treatment trial, hampering stocks Tuesday.

(Image credit: Getty Images)

Investors had plenty to chew on Tuesday, and it showed in a down day for stocks.

The big headline out of the gate was Johnson & Johnson (JNJ, -2.3%) pausing late-stage trials for its promising COVID-19 vaccine due to an "unexplained illness," which, as we explained when AstraZeneca (AZN) was forced to do the same, isn't uncommon and doesn't necessarily spell doom for the treatment.

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

Kyle Woodley was long AAPL and QQQ as of this writing.

To continue reading this article
please register for free

This is different from signing in to your print subscription

Why am I seeing this? Find out more here

Kyle Woodley

Kyle Woodley is the Editor-in-Chief of WealthUp, a site dedicated to improving the personal finances and financial literacy of people of all ages. He also writes the weekly The Weekend Tea newsletter, which covers both news and analysis about spending, saving, investing, the economy and more.

Kyle was previously the Senior Investing Editor for, and the Managing Editor for before that. His work has appeared in several outlets, including Yahoo! Finance, MSN Money, Barchart, The Globe & Mail and the Nasdaq. He also has appeared as a guest on Fox Business Network and Money Radio, among other shows and podcasts, and he has been quoted in several outlets, including MarketWatch, Vice and Univision. He is a proud graduate of The Ohio State University, where he earned a BA in journalism. 

You can check out his thoughts on the markets (and more) at @KyleWoodley.